Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data

Table 1 Correlations of Beclin1, LC3, and 4E-BP1 expression with clinicopathological characteristics in 68 advanced colorectal cancer patients n (%)

Variable	n = 68	Beclin1 expression			LC3 expression			4E-BP1 expression
		Low	High	P-value	Low	High	P-value	Low	High	P-value
Sex				0.061			0.372			0.571
Male	44 (64.7)	13	24		12	25		8	28
Female	24 (35.3)	2	17		4	15		3	16
Age (yr)				0.119			0.167			0.865
< 65	55 (80.9)	10	35		11	34		9	35
≥ 65	13 (19.1)	5	6		5	6		2	9
Family history of cancer				0.593			0.151			0.382
Yes	13 (19.1)	2	8		1	9		1	9
No	55 (80.9)	13	33		15	31		10	35
Location1				0.862			1.000			0.634
Left	50 (73.5)	11	31		12	30		2	33
Right	18 (26.5)	4	10		4	10		9	11
Pathological grade				0.349			0.349	8		0.897
1 + 2	44 (64.7)	8	30		8	30		8	29
3	18 (26.4)	5	10		5	10		3	12
NA	6 (8.9)
T stage				0.618			0.618			0.911
T1 + T2 + T3	41 (60.3)	9	24		9	24		6	26
T4	22 (32.4)	4	15		4	15		4	16
NA	5 (7.3)
N stage				0.058			0.058			0.654
No	22 (32.4)	6	9		6	9		4	12
N1 + N2	36 (52.9)	5	28		5	28		6	25
NA	10 (14.7)
Synchronous/metachronous metastasis				0.020			0.058			0.162
Synchronous metastasis	24 (35.3)	1	18		2	17		5	12
Metachronous metastasis	43 (63.2)	13	23		13	23		5	32
NA	1 (1.5)
KRAS				0.044			0.044			0.651
Wild type	45 (66.2)	13	24		13	24		7	30
Mutant type	10 (14.7)	0	9		0	9		2	6
NA	13 (19.1)

Location: The primary tumor location was classified as right-sided or left-sided according to the splenic flexure. CRC: Colorectal cancer; LC3: Microtubule-associated protein 1A/B-light chain 3; NA: Not applicable; 4E-BP1: 4E-binding protein 1.